Cipla Overtakes GSK to Become Top Indian Pharma Company (India)
This article was originally published in PharmAsia News
So far in 2007, Cipla has emerged ahead of its competitors to become the top pharmaceutical company in the Indian domestic market with a share of 5.17 percent. Its closest competition is GlaxoSmithKline at 4.89 percent. Local leaders Ranbaxy, Nicholas Piramal, and Zydus Cadila followed up in the third, fourth, and fifth positions respectively. When international sales were taken into account, it was Ranbaxy that came out on top with the highest overall revenues of any Indian pharmaceutical manufacturer. Ranbaxy took the spot from Dr. Reddy's Laboratories, which held the lead position up until two months ago. (Click here for more
You may also be interested in...
MUMBAI - Europe's largest drugmaker GlaxoSmithKline has sued Indian drug maker Lupin for infringement of its patents for anti-AIDS drug Combivir in the U.S
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.